tirzepatide cardiovascular outcomes trial results august 2025 Effects of on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT Preliminary results on the Tirzepatide

A Standardized dataset of a spontaneous adverse event reporting system

Stepping back to 12.5 mg or even 10 mg often resolves the side effects while maintaining meaningful weight loss

We used an intention-to-treat approach and, therefore, patients with no incident AF were censored at death or the last encounter, whichever came first

NieLJLiangJShanFWangBSMuYYZhouXHet al

While these FDA-approved medications are highly effective for weight reduction, patients and clinicians often have questions about their gastrointestinal safety profile

All patient-outcome figures referenced here come directly from Telos Rx's own website